Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Drugs Market Report 2026-2036" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue for the Rheumatoid Arthritis Market will surpass US$37 billion in 2026
This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Rising Adoption of Advanced Disease-Modifying Therapies
The rheumatoid arthritis drugs market is increasingly shaped by the rising adoption of advanced disease-modifying therapies, which are now firmly embedded in contemporary treatment strategies for moderate-to-severe disease. Clinicians are moving toward earlier intervention and timely treatment escalation, resulting in broader and more sustained utilisation of biologic and targeted synthetic therapies across multiple lines of treatment.
These medicines are no longer used solely for symptom management but are central to preventing structural joint damage, reducing disability, and preserving long-term physical function, thereby extending average treatment duration. The growing availability of therapies with distinct mechanisms of action has strengthened physicians'ability to personalise treatment pathways and maintain disease control following initial treatment failure. This shift toward long-term, sequential treatment patterns is deepening patient retention on therapy and reinforcing consistent, stable demand for advanced rheumatoid arthritis drugs across key global markets.
What would be the Impact of US Trade Tariffs on the Global Rheumatoid Arthritis Market?
U.S. trade tariffs would primarily affect the global rheumatoid arthritis market through higher input costs and increased supply-chain complexity within the injectable biologics ecosystem. The treatment landscape remains heavily reliant on biologic therapies that depend on robust cold-chain logistics and specialised primary packaging and delivery components, including prefilled syringes, needles, and other medical consumables. Under the U.S. Section 301 tariff framework and subsequent revisions, higher duties on items such as syringes and needles have raised concerns among industry participants and healthcare providers regarding rising procurement costs and potential disruptions to the availability of essential medical products.
For manufacturers, the immediate consequence would be margin compression and greater working-capital pressure, particularly for companies dependent on tariff-exposed supply chains, including China-linked sources for certain medical components. The challenge is further compounded by lengthy regulatory validation processes that limit the speed at which alternative suppliers can be qualified.
This risk is especially pronounced for rheumatoid arthritis biologics delivered via prefilled syringes or auto-injectors, where non-tariffed active drug substances may still be subject to cost inflation arising from tariff-affected packaging and device components. Should U.S. tariff measures extend to finished pharmaceutical products, as discussed in recent policy statements in 2025, multinational firms may face heightened pricing and supply uncertainties, potentially accelerating strategies such as localisation, dual sourcing, and increased inventory buffering.
Key Questions Answered
- How is the Rheumatoid Arthritis market evolving?
- What is driving and restraining the Rheumatoid Arthritis market?
- How will each Rheumatoid Arthritis submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
- How will the market shares for each Rheumatoid Arthritis submarket develop from 2026 to 2036?
- What will be the main driver for the overall market from 2026 to 2036?
- Will leading Rheumatoid Arthritis markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
- Who are the leading players and what are their prospects over the forecast period?
- What are the Rheumatoid Arthritis projects for these leading companies?
- How will the industry evolve during the period between 2026 and 2036? What are the implications ofRheumatoid Arthritis projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the Rheumatoid Arthritis market?
- Where is the Rheumatoid Arthritis market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Market Dynamics
Market Driving Factors
- Uptake of Cost-effective Biosimilars
- Rising Cases of RA
- Broader Access to Biologics Through Subsidies and Insurance Programmes
- Growing Clinical Research in Personalised Rheumatoid Arthritis Therapies
- Integration of Digital Health Platforms in Rheumatology Care
Market Restraining Factors
- Safety Concerns with Long-term Immunosuppressive Therapy
- Loss of Patent Exclusivity
- Persistent Diagnostic Delays in Primary Care
- Revenue Compression Due to Biosimilar Entry
Market Opportunities
- Emerging JAK Inhibitors
- Technological Advancements
- Increasing Organic Strategies Among Market Players
Leading Companies
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Sandoz Group AG
- Regeneron Pharmaceuticals Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- UCB S.A.
- Johnson & Johnson
- Amgen Inc.
- Eli Lilly and Co (Lilly)
- Regeneron Pharmaceuticals Inc.
Segments Covered in the Report
Type of Molecule
- Pharmaceuticals
- Biopharmaceuticals
Route of Administration
- Oral
- Injectable
- Topical
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Companies Featured
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Sandoz Group AG
- Regeneron Pharmaceuticals Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- UCB S.A.
- Johnson & Johnson
- Amgen Inc.
- Eli Lilly and Co (Lilly)
- Regeneron Pharmaceuticals Inc.
- Adaptive Biotechnologies Corporation
- Age Labs
- Alvotech
- AnaptysBio
- Artivila Biopharma
- CDR-Life, Inc.
- Celltrion Healthcare
- Changchun GeneScience Pharmaceutical Co., Ltd
- Cullinan Therapeutics
- CVS Caremark
- CVS Health
- Elevara Medicines
- Fuji Pharma
- Lifordi Immunotherapeutics
- Lipum AB
- Mankind Pharma
- Rise Therapeutics
- Sonoma Biotherapeutics
- American College of Rheumatology (ACR)
- Arthritis Australia (AA)
- Arthritis Foundation (AF)
- Arthritis Ireland (AI)
- Arthritis Research UK / Versus Arthritis (Versus Arthritis)
- Asia Pacific League of Associations for Rheumatology (APLAR)
- British Society for Rheumatology (BSR)
- Canadian Rheumatology Association (CRA)
- European Alliance of Associations for Rheumatology (EULAR)
- International League of Associations for Rheumatology (ILAR)
- Japanese College of Rheumatology (JCR)
- National Rheumatoid Arthritis Society (NRAS)
- Pan-American League of Associations for Rheumatology (PANLAR)
- Rheumatology Nurses Society (RNS)
- World Health Organization (WHO)
For more information about this report visit https://www.researchandmarkets.com/r/k3pt7s
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
